[PDF][PDF] Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after …

S Hironaka, S Ueda, H Yasui, T Nishina, M Tsuda… - J clin …, 2013 - researchgate.net
… Collection and assembly of data: Shuichi Hironaka, Shinya Ueda, … Shuichi Hironaka,
Chiba Cancer Center, Chiba; Shinya Ueda and Isamu Okamoto, Kinki University …

Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors

…, A Tsuya, Y Hasegawa, M Terashima, S Ueda… - Clinical Cancer …, 2009 - AACR
Purpose: YM155, a novel molecular targeted agent, suppresses survivin, a member of the
inhibitor of apoptosis protein family that is overexpressed in many tumor types. The aim of this …

Effects of B4C doping on critical current properties of MgB2 superconductor

A Yamamoto, J Shimoyama, S Ueda… - Superconductor …, 2005 - iopscience.iop.org
The relationships between microstructures, crystallinity and critical current properties for B 4
C doped MgB 2 bulks, MgB 2− 5x (B 4 C) x with x= 0, 0.04, 0.1, 0.2 and 0.4, were …

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority …

…, K Nishikawa, Y Makari, K Amagai, S Ueda… - The lancet …, 2017 - thelancet.com
Background Weekly administration of solvent-based paclitaxel is one of the standard second-line
chemotherapy regimens for advanced gastric cancer. Nanoparticle albumin-bound …

Improved critical current properties observed in MgB2 bulks synthesized by low-temperature solid-state reaction

A Yamamoto, J Shimoyama, S Ueda… - Superconductor …, 2004 - iopscience.iop.org
MgB 2 bulks were synthesized by the solid-state reaction of Mg and B at 600 C and their
superconducting properties were compared with samples heated at 850 C. The samples heated …

Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy

…, M Taguri, Y Honma, H Takahashi, S Ueda… - The …, 2012 - academic.oup.com
Background. No standard chemotherapy regimen has been established for unresectable or
recurrent small bowel adenocarcinoma (SBA). Methods. Clinical courses of 132 patients with …

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors

…, W Okamoto, M Miyazaki, R Morinaga, S Ueda… - Molecular cancer …, 2010 - AACR
BIBF 1120 is an oral multitargeted tyrosine kinase inhibitor that blocks the activity of vascular
endothelial growth factor (VEGF) and other growth factor receptors. We have done a phase …

[HTML][HTML] Long-term use of modern Portland cement concrete: The impact of Al-tobermorite formation

…, J Rymeš, A Aili, S Sawada, O Kontani, S Ueda… - Materials & Design, 2021 - Elsevier
The distribution of compressive strength in thick concrete members exposed to various
environments in a nuclear power plant undergoing decommissioning is investigated. X-ray …

High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by …

Y Kidera, T Satoh, S Ueda, W Okamoto… - International journal of …, 2011 - Springer
Background Oxaliplatin is a third-generation platinum compound and a key agent for the
management of colorectal cancer. Patients treated with oxaliplatin are at risk for hypersensitivity …

Cytochrome P450 Monooxygenase CYP716A141 is a Unique β-Amyrin C-16β Oxidase Involved in Triterpenoid Saponin Biosynthesis in Platycodon grandiflorus

K Tamura, Y Teranishi, S Ueda, H Suzuki… - Plant and Cell …, 2017 - academic.oup.com
The roots of Platycodon grandiflorus are widely used as a crude drug. The active components
include a variety of triterpenoid saponins. Recent studies have revealed that Cyt P450 …